Table 3.
Annual All-Cause and SCD-Related HCRU and Costs
| Follow-Up All-Cause HCRU and Costs in the First 12 Months | |||
|---|---|---|---|
| Facility Type | % Patients With ≥1 Visit | Mean Costs | Median of Costs |
| Inpatient | 56.3% | US$17 535 | US$1590 |
| Outpatient other | 56.0% | US$6891 | US$0 |
| Pharmacy | 95.2% | US$3898 | US$0 |
| Long-term care (LTC) | 3.0% | US$2665 | US$169 |
| Outpatient hospital | 87.4% | US$2081 | US$0 |
| Outpatient ER | 73.3% | US$592 | US$0 |
| Outpatient office | 83.6% | US$397 | US$0 |
| Hospice | 0.1% | US$34 | US$3577 |
| Lab | 55.5% | US$33 | US$0 |
| Ambulatory surgery center | 4.5% | US$12 | US$281 |
| Total (inpatient + outpatient + LTC + pharmacy) Cost | US$34 136 | US$12 691 | |
| Follow-Up SCD-Related HCRU and Costs in the First 12 Months | |||
| Facility Type | % Patients with ≥1 visit | Mean Costs | Median of Costs |
| Inpatient | 42.7% | US$15 237 | US$0 |
| Pharmacy | 82.0% | US$2584 | US$0 |
| Outpatient hospital | 65.2% | US$723 | US$0 |
| Outpatient other | 28.7% | US$685 | US$0 |
| Long-term Care (LTC) | 1.2% | US$498 | US$0 |
| Outpatient ER | 49.9% | US$402 | US$0 |
| Outpatient office | 47.7% | US$64 | US$0 |
| Lab | 27.1% | US$8 | US$0 |
| Ambulatory surgery center | 1.7% | US$5 | US$0 |
| Hospice | 0.0% | US$0 | US$0 |
| Total (inpatient + outpatient + LTC + pharmacy) Cost | US$20 206 | US$1204 | |
Note: Health care costs were examined among patients with FFS Medicaid plan.
Abbreviations: LTC, long-term care; SCD, sickle cell disease; HCRU, health care resource utilization; FFS, fee-for-service; ER, emergency department